Skip to main content

MAINZ BIOMED N.V.

corporate_fare Company Profile

MAINZ BIOMED N.V.

Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes its IVD kits to third-party laboratories. The company has a collaboration agreement with Thermo Fisher Scientific Inc. for the development and commercialization of colorectal cancer screening product. Mainz Biomed N.V. was founded in 2008 and is based in Mainz, Germany.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed MYNZ - Latest Insights

MYNZ
Mar 12, 2026, 9:24 AM EDT
Filing Type: PRE 14A
Importance Score:
10
MYNZ
Mar 11, 2026, 7:35 AM EDT
Filing Type: 8-K
Importance Score:
8
MYNZ
Feb 17, 2026, 7:30 AM EST
Filing Type: 8-K
Importance Score:
10
MYNZ
Feb 10, 2026, 5:00 PM EST
Filing Type: 8-K
Importance Score:
8